Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors

Clinical & Experimental Metastasis, Oct 2015

There is accumulating evidence indicating that aldehyde dehydrogenase (ALDH) activity selects for cancer cells with increased aggressiveness, capacity for sustained proliferation, and plasticity in primary tumors. However, emerging data also suggests an important mechanistic role for the ALDH family of isoenzymes in the metastatic activity of tumor cells. Recent studies indicate that ALDH correlates with either increased or decreased metastatic capacity in a cellular context-dependent manner. Importantly, it appears that different ALDH isoforms support increased metastatic capacity in different tumor types. This review assesses the potential of ALDH as biological marker and mechanistic mediator of metastasis in solid tumors. In many malignancies, most notably in breast cancer, ALDH activity and expression appears to be a promising marker and potential therapeutic target for treating metastasis in the clinical setting.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs10585-015-9755-9.pdf

Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors

Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors Mauricio Rodriguez-Torres 0 1 2 3 4 Alison L. Allan 0 1 2 3 4 0 Department of Oncology, Schulich School of Medicine and Dentistry, Western University , London, ON , Canada 1 Department of Anatomy & Cell Biology, Schulich School of Medicine and Dentistry, Western University , London, ON , Canada 2 London Regional Cancer Program, London Health Sciences Centre , London, ON , Canada 3 London Regional Cancer Program , Room A4-132, 790 Commissioners Road East, London, ON N6A 4L6 , Canada 4 Lawson Health Research Institute , London, ON , Canada There is accumulating evidence indicating that aldehyde dehydrogenase (ALDH) activity selects for cancer cells with increased aggressiveness, capacity for sustained proliferation, and plasticity in primary tumors. However, emerging data also suggests an important mechanistic role for the ALDH family of isoenzymes in the metastatic activity of tumor cells. Recent studies indicate that ALDH correlates with either increased or decreased metastatic capacity in a cellular context-dependent manner. Importantly, it appears that different ALDH isoforms support increased metastatic capacity in different tumor types. This review assesses the potential of ALDH as biological marker and mechanistic mediator of metastasis in solid tumors. In many malignancies, most notably in breast cancer, ALDH activity and expression appears to be a promising marker and potential therapeutic target for treating metastasis in the clinical setting. Aldehyde dehydrogenase tumors; Cancer stem cell; Biomarker - & Alison L. Allan Introduction Metastasis is a life-threatening systemic condition, with ninety percent of all cancer deaths resulting from cancer cell dissemination from the primary tumor to distant vital organs [1]. Navigation of the metastatic cascade is a complex, multistep process involving multiple tumor cell phenotypes, body compartments, and accelerated evolutionary cell trajectories [2]. Accordingly, in spite of enormous and earnest progress in elucidating the mechanisms that drive metastasis, the mortality of metastatic cancer has improved very little in the last several decades [3]. Despite the deadly nature of metastasis, it is a remarkably inefficient process. In fact, only a small fraction of cancer cells that survive in the systemic circulation are able to give rise to clinically relevant metastases [4]. Therefore, the identification, isolation, and characterization of potential metastasis-initiating cell (MIC) subpopulations has become a priority for many metastasis research groups including ours. One of the most attractive candidates for MICs are putative cancer stem cells (CSCs), which have been identified in a diverse array of hematopoietic and solid tumor types (reviewed in [5] and [6]). These CSC subpopulations can be defined by their capacity for sustained self-renewal and the ability to give rise to the heterogeneous population of cancer cells that make up a tumor. Importantly, it has also been shown that cells with a CSC phenotype characterized by high aldehyde dehydrogenase (ALDH) activity have an enhanced capacity for metastatic behavior in vitro (adhesion, colony formation, migration, and invasion) and/or metastasis in vivo [7–11], supporting the hypothesis that CSCs might act as the MIC subpopulation. In the past several decades, increasing evidence has supported the role of ALDH as a biological marker for stem-like cancer cells and aggressive tumor cell behavior, as well as an indicator of poor clinical outcome with particular prominence in breast cancer experimental models and clinical studies (reviewed in [5, 12–15] ). In addition to its role as a detoxifying enzyme and key mediator of stem/ progenitor cell expansion and differentiation, the functional and mechanistic involvement of ALDH in tumor initiation and progression has become a topic of considerable interest in the cancer field. While the involvement of ALDH in primary tumor formation, therapy resistance, and malignant behavior in vitro has been extensively described in the literature (reviewed in [5, 12–14, 16] ), the role of ALDH in metastasis has been less evident. The purpose of this review is to highlight the most recent evidence supporting a specific role for ALDH in metastasis, both in pre-clinical mechanistic studies and in vivo models, as well as in the clinical setting. Clarification of the tumor types affected, the isoforms implicated, and the underlying molecular mechanisms of ALDH in driving metastasis is necessary in order to achieve effective translational targeting of this important enzyme. The human ALDH superfamily Nineteen different ALDH functional genes and multiple splice variants have been characterized to date. Although they are widely expressed in multiple different tissues, these ALDH isoforms display tissue- and organ-specific expression patterns and have also been found in various cellular subcompartments including the cytosol, nucleus, mitochondria, and endoplasmic reticulum (reviewed in [5] ). In these locations, ALDH catalyzes the oxidation of aldehydes to their corresponding carboxylic acids. For example, different ALDH families are capable of detoxifying highly reactive aldehydes that are products of lipid peroxidation (ALDH1, ALDH3, ALDH8) [17–19]. Others are critical regulators of the retinoic acid pathway through involvement in the catalysis of retinaldehyde to retinoic acid, and therefore play an important role in stem and progenitor cell expansion and differentiation (ALDH1A1, ALDH1A2, ALDH1A3) [20]. ALDH also has been found capable of inactivating xenobiotics, including the alkylating agent cyclophosphamide (CP) and analogous chemotherapeutic drugs (ALDH1A1, ALDH3A1) [21]. In addition, it has been observed that ALDH is mechanistically involved in other diverse cell activities including structural and osmoregulatory functions (ALDH1A1, ALDH3A1, ALDH7A1) [14, 22]. Importantly, the ability of ALDH to regulate cell proliferation and selfprotection is believed to contribute its involvement in mediating CSC capabilities such tumor progression, phenotypical heterogeneity, and therapy resistance [5]. Functional role of ALDH in cancer ALDH and retinoic acid signaling in cancer cells The retinoic acid signaling pathway has been implicated in normal and cancer cell function including the regulation of gene expression and development [23–26]. In tumor biology, the retinoic acid pathway appears to play a dualistic role involving epigenetic context-dependent differential gene expression, mediation of apoptotic pathways, and immune system regulation [10, 20]. The human cytosolic ALDH1A subfamily (made up of ALDH1A1, ALDH1A2, and ALDH1A3) irreversibly oxidizes retinaldehyde to retinoic acid (RA). Subsequently, RA is translocated to the nucleus where it is able to regulate the transcriptional activity of more than 500 genes through activation of retinoic acid receptor (RAR), retinoic X receptor (RXR), and nuclear hormone receptors peroxisome proliferator activated receptor beta/delta (PPAR/b/d). RA exerts differential effects on tumor growth in a cell context-dependent manner. It has been found that retinoic acid activation of RARs and RXRs is followed by cell cycle arrest and differentiation due to increased transcription of tumor suppressor factors, whereas RA activation of PPARs has been found to mediate the increased expression of oncogenes and subsequent cell cycle progression observed in other experimental model systems (reviewed in [20]). In addition, it has been observed that the influence of RA on tumor growth might be mediated by epigenetic silencing of RA-inducible tumor suppressors [10, 27]. Importantly, RA-producing ALDH isoforms, including ALDH1A1 and ALDH1A3 (but not ALDH1A2), are among the most common ALDH isoforms associated with a diverse arrange of hematopoietic and solid tumors. There is accumulating evidence that their increased expression selects for tumor cell subpopulations exhibiting stem-like or aggressive tumor cell phenotypes, indicating that the tumorigenic ‘‘branch’’ of the retinoic acid pathway might be co-opted in some tumors and/or that other non RAdependent functional roles of ALDH1A1 and ALDH1A3 might be involved in tumorigenesis [7, 9, 10, 28]. For example, ALDH1A1 and ALDH1A3 have been shown to play functional roles in lung and breast cancer cell migration and invasion, although the mechanisms underlying this behavior have not been established [10, 29, 30]. It is of note that RA has been used to dramatically improve clinical outcome in patients with acute promyelocytic leukemia (APL); where ninety-eight percent of patients with this disease carry a fusion of the PML and RARa genes that impairs the ability of RARa to induce hematopoietic stem/progenitor cell differentiation at physiological levels of RA [31, 32]. However, attempts to use RA to induce tumor cell differentiation in other cancer types have shown mixed results at best in clinical trials (reviewed in [20] and [16]). The potential causes of the disparate results obtained after targeting the retinoic acid pathway in cancer are discussed later in this review. ALDH plays a self-protective role in cancer cells There is increasing evidence implicating ALDH in cancer cell self-protection against both endogenous and exogenous threats. Antioxidant and substrate-specific drug inactivation are among the key mechanisms underlying these capabilities. For example, ALDH has a NADPH recycling function that is believed to support antioxidant cell capabilities. In addition, it has been observed that ALDH is often co-expressed with antioxidant factors and drug efflux channels in cells with high ALDH activity [22, 33–39]. ALDH1A1 and ALDH1A3 are capable of enzymatic inactivation of alkylating agents such as CP and other oxazaphosphorines [40–43]. Moreover, ALDH appears to confer resistance to drugs other than CP and analogues including doxorubicin, cisplatin, arbinofuranosyl citidine (Ara-C), temozolemide and taxanes [28, 44–47], although the mechanisms underlying this are less clear. A comprehensive review of ALDH involvement in chemotherapy and radiotherapy resistance has recently been published by Januchowski et al. [21]. Thus, ALDH is not only involved in physiologic and cancer cell proliferation and differentiation, but also in promoting tumor cell survival through direct inactivation, indirect expulsion of xenobiotics, and enhancement of the oxidative stress resistance response. ALDH as a marker for cancer stem cells Assessment of ALDH in cancer research Different approaches have been used to quantify ALDH in cancer cells and tumor tissue. Early methods for determining ALDH levels relied on measuring enzyme kinetics or immunoblotting of enzymes released after cell lysis, in addition to immunohistochemical detection. However, these methods are flawed by antibody cross-reactivity between enzyme isoforms and enzyme structural instability [48, 49]. An alternative and more recent approach consists of measuring ALDH activity in viable cells by quantifying the ALDH-mediated intracellular retention of the fluorescent compound BODIPY-aminoacetate (BAA-) using flow cytometry-based methods [7, 23, 50–52]. This functional assay is commercialized as the ALDEFLUORTM assay and depends on the conversion of the uncharged ALDH substrate BODIPY amino acetaldehyde (BAAA), which freely diffuses in and out of the cell, into the negatively charged BAA-compound. As a result, after addition of BAAA, cancer cell subpopulations with elevated activity of ALDH (ALDHhi) become highly fluorescent and can be identified using flow cytometry gating criteria. The ALDHhi cell subset can be distinguished when compared to cells treated with the ALDH1 inhibitor 4-(diethylamino) benzaldehyde (DEAB), which is used as a reference control. Although the ALDEFLUORTM assay works well in various human models, there is controversy about its adequacy for identifying cancer stem cells in murine models given disparate results among groups isolating murine HSCs using this technique [53–56]. However, enrichment of murine CSCs have been recently reported using the ALDEFLUORTM assay in two different models of mouse breast cancer [57, 58]. In addition, attempts at in vivo stem cell labeling have employed ALDH radiolabeled substrates. However, the resultant charged compounds were not polar enough to be retained into the cells [59]. Early reports identified ALDH1 as the main ALDH enzyme family responsible for the enzymatic activity reported using the ALDEFLUORTM assay [52, 60]. However, recent controversy has emerged regarding the family and subfamily isoforms acting on the BAAA substrate and thus responsible for the readout in this assay. This distinction is of importance given the ample and tissue-specific distribution of ALDH isoforms in normal tissue, the reliance on the ALDEFLUORTM assay for isolation of viable CSCs for subsequent downstream assessment, and differential roles of different ALDH1 isoforms in tumorigenesis and metastasis [10]. In breast cancer, mixed results have been reported regarding the specific ALDH1A isoenzyme involved in tumorigenesis and the ALDEFLUORTM assay, with some groups reporting ALDH1A1 as the main enzyme involved and others showing that ALDH1A3 is the accountable isoform [9, 10, 61, 62]. Recent research by our group using human breast cancer cell lines indicate that although both isoforms are involved in different phases of the metastatic cascade, 50 % of the ALDEFLUORTM activity is driven by the ALDH1A3 isoform with no significant participation of ALDH1A1 in this assay (our unpublished data). In addition, other studies have found enzymatic participation of ALDH1A1, 1A2, 1A3, 2, 7A1 and 8 in the ALDEFLUORTM assay in other tumor types [22, 63–65]. Thus, multiple ALDH isoforms may contribute to both the readout of the ALDEFLUORTM assay and to cellular function in tumorigenesis in a tissue-specific manner. It is important to clarify that, by current nomenclature, the term ALDH1 does not accurately describe any of the isoforms of the ALDH superfamily [12] and could refer to ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B, ALDH 1L1, or ALDH1L2. This is a major problem in the ALDH/cancer stem cell literature, where ALDH1A1 is often used interchangeably with ALDH1 or ALDH. Further confusion arises when ALDEFLUORTM positivity is referred to as ALDH1 activity or positivity. To address this ambiguity, in the current review we will refer to ALDEFLUORTM positive cells or ALDEFLUORTM activity whenever the source refers to a phenotype identified using the ALDEFLOUORTM assay. Notably, Pors et al. [12] recently reported that the specific isoform identified using BD Biosciences clone 44 or Abcam ab52492 antibodies against ALDH1 is ALDH1A1. In this review, we will therefore clarify this whenever ALDH1 expression is reported by authors using either of these antibodies. In addition, if the isoform specificity of the ALDH1 antibody could not be established, this will also be noted. Recent evidence supporting ALDH as a CSC marker Multiple markers have been used for enriching cells with stem-like properties from human tumor primary tissue and human cancer cell lines, and this is reviewed exhaustively elsewhere in the literature [6, 66–70]. We have previously reviewed the relevance of ALDH as a marker for normal and cancer stem cells [5]. Thus, for this review we have summarized the latest findings regarding the importance of ALDH as a cancer stem cell marker since 2010 (summarized in Table 1). ALDH and metastasis While there is growing evidence supporting the use of ALDH as a CSC marker and implicating it as having an important functional role in tumor cell self-protection, differentiation, expansion, and therapy resistance, less is known about its functional role in mediating metastasis. In this section we will review the mechanistic involvement of ALDH in metastasis based on experimental evidence derived from assessment of in vitro of cellular behaviors contributing to metastasis, in vivo animal models of metastasis, and patient-derived metastasis samples. Functional association of ALDH with in vitro cell behaviors related to metastasis Different in vitro assays have been used to model and estimate potential metastatic activity in vivo [71]. Clonogenic assays involving loss of substrate adherence or serum-free media, including colony formation in soft agar and tumorsphere growth in ultra-low attachment plates, are correlated with tumorigenicity and stemness. Therefore, they are often used to evaluate the capability of cancer cells to initiate metastatic growth in vivo [72–75]. Assessments of migration and invasion in vitro have also been used to estimate metastatic potential in vivo [71, 72]. In addition, given the intrinsic resistance of metastases to chemotherapy and radiotherapy, in vitro assessment of therapy response has also proven to be useful [72, 74, 76, 77]. ALDH and several of its isoforms have been recently evaluated for and positively correlated with multiple in vitro cell behaviors that are surrogates of metastatic behavior in vivo. Tumor cells displaying high ALDEFLUORTM activity have been demonstrated to have enhanced motility and ability to invade through a 3D basement membrane in breast cancer [7, 78], ovarian cancer [79, 80], osteosarcoma [36, 81], esophageal cancer [82], and prostate cancer [11, 83]; as well as increased therapy resistance in breast cancer [28, 84], ovarian cancer [79], osteosarcoma [85], and prostate cancer [86]. ALDEFLUORTM-positive cells have also been reported to exhibit increased capacity to form tumorspheres in breast cancer [8, 15, 52, 87], human malignant fibrous histiocytoma (HMFH) [88], ovarian cancer [80, 89, 90], brain tumors [91, 92], prostate cancer [11], head and neck squamous cell carcinoma (HNSCC) [93], colon cancer [94, 95], non-squamous cell lung cancer (NSCLC) [96–98], esophageal cancer [82], and cervical cancer [99]. Interestingly, ALDH-positive cells display additional stem-like behaviors such as resistance to hypoxia in ovarian cancer [79] and the capacity for asymmetric division in brain tumor cells [91]. Several specific ALDH isoforms have been correlated with in vitro metastatic behavior. For example, ALDH1A1 expression has been reported to correlate with increased in vitro clonogenic activity in NSCLC [29, 100, 101], esophageal cancer [102], ovarian cancer [90], pancreatic cancer [103], and renal cancer [104]. This ALDH isoenzyme has also been correlated with increased migratory capabilities in lung cancer [29], renal cancer [104], and esophageal cancer [29] and in vitro therapy resistance in lung cancer [105], melanoma [65, 106], and renal cancer [104]. Other ALDH isoforms have been mechanistically associated with metastatic behavior in vitro, including ALDH1A3 in breast cancer [9, 10], melanoma [65], pancreatic cancer [107] and brain cancer [108]; ALDH3A1 in prostate cancer [109] and liver cancer [110]; and ALDH7A1 in prostate cancer [11]. In summary, increasing evidence from in vitro studies suggests a mechanistic role for ALDH in metastasis and have laid the groundwork to further the study of the involvement of this enzyme in metastatic activity in vivo. r ] ] e o 0 3 s e 8 o d ]94 [18 .sv ,1 th ra ,1361 teoyp tssae i[ssa9 ]a4dn /rdog tirssaenov ,,l[e53110on-?ehnp24CD tiissaennom tt/rsaeaodnm [rae18nowm ,]48128 ,,]an282169 t][rae26pyh ][recca16n ,,]58141380 b H a 4 se ] ] g 1 [ o t [ il/iitrscacnpogono ititcaeodhLwDA liiltrccaeconooum iiteobnd4hCwDm rrseaeedxpLAHD itrr[rsayu119omm rrrr[ececeou181nm irecoooyunnnmm ,,it[h6201TBCN ttrrssecaeaedugom ][9 trrsseeceoponhom liilirrrfssaeakbom liiltrccaecnoooum l ss o c cn p u o w n o a o C a P I T M I P F P c F a In In In In In A D In In In In In C L 8 H 1 , 1 D H D D D n D D D D e 8 I I T I I I I I I A r D D 6 C I I H H p D D s D C 2 A a H H p 0 o D D s 9 N H H H ]1 H ] ] ] , ] 0 ] n 1 , 9 5 6 5 4 o 5 2 [9 [6 01 [1 01 ita [1 [8 TM TM [g TM ] [g iitp TM ] TM R R in R 2 in c R 49 t 4 t e O O ] t O 1 t ] ] r O 1 LU LU 39 lob ]5 LU ]0 ,4 lob 40 30 in op U , F F F 1 no [6 F 15 10 no [1 [1 ta un ] FL 110 E E ,6 u R E [ [ u R R om m 07 E [ D D 0 m C D C C m C C r D C L L 1 m P L H H m P P h im [1 L H A A I q A I I I q q C A I 1 m A r m 1 o r f o ] H o f 39 ]6 D is so ,61 ,01 ] (LA (no ]4 ]3 ]7 ]4 ]0 ]2 ion ]2 10 [65 [65 ]0 ]42 ) [10 [10 [10 ] [19 [11 10 ](2 ) [10 ] , 5 ) 1 , 9 5 1 3 [1 ] [1 ted 1 1 3 5 3 1 28 [8 ted 1 [9 [6 1A 1A 1 21 1 ta 1A 1A 1A [1 1A 3A [ 1 ta 1A H H H H H [ H o H H H H H H H H o H r n n D D D D D e D n D D D D D D D D n D L L L L L p L a L L L L L L L L a L A A A A A A A A A A A A A A A Croker et al. [7] and Charafe-Jauffret et al. [111], using the ALDHhiCD44?CD24- and ALDHhi and phenotypes respectively, provided the first direct experimental evidence implicating ALDHhi cells in breast cancer metastasis in vivo. Moreover, it was shown that ALDHhiCD44?CD24- cells were the only cancer cell subpopulation capable of metastasizing beyond the lungs in a pattern that mirrors the clinical behavior of breast cancer [7]. Concurrently, it was also reported that ALDH1A1?CD44?CD24? cells correlated with metastatic activity in matched primary and metastatic samples from pancreatic cancer [112]. Subsequent studies have shown that high ALDEFLUORTM activity enriches for cells with increased metastatic capability in vivo in prostate cancer [83, 113, 114], breast cancer [15, 33], HNSCC [93], osteosarcoma [81], esophageal cancer [102], ovarian cancer [79], hepatic cancer [95], and adenoid cystic carcinoma [115]. More recently, other studies have further investigated the specific ALDH isoenzymes correlated with metastatic activity in vivo. For example, ALDH7A1 has been implicated in prostate cancer metastatic activity after left ventricular injection (LVI) of a prostate cancer cell line [11], while ALDH3A1 has been shown to be associated with metastasis using a mouse tail vein injection model [109]. ALDH1A3 has been observed to be involved in metastasis in vivo in breast cancer after cancer cell xenotransplantation into mouse models [10]. It has also been reported that inhibition of ALDH1A1 by RNA interference in melanoma cell results in reduced metastatic ability in vivo [106], providing functional validation and indicating that ALDH is not only a biological marker for enhanced metastatic ability, but also plays a functional role in metastasis in vivo. Interestingly, in one study, ALDH1A3 was found to promote or inhibit breast cancer metastasis depending on the specific epigenetic context framing retinoic acid signaling in vivo [10]. Another elegant study reported that immune targeting of breast CSCs cancer stem cells using ALDH1A1-specific CD8? T cells resulted in reduced metastatic activity of breast cancer cells in vivo [116]. Interestingly, this study reported that ALDH1A1 was the main ALDH isoenzyme determining of ALDEFLUORTM assay activity. Association of ALDH and metastasis in clinical tissue samples The association of ALDH and metastases in the clinical setting has been of interest since the late 1980s, when Marselos et al. showed increased enzymatic activity of ALDH (no isoform specified) in metastatic lesions from colon cancer compared with normal adjacent tissue [117]. This study would contrast with another early publication indicating that ALDH activity was not elevated in the serum of patients with metastatic hepatic cancer when compared with serum of patients with non-metastatic cancers [118]. ALDH expression has been assessed in matched primary tumor and metastases tissues in breast cancer [119], colorectal cancer [94, 120, 121], pancreatic cancer [112], and hepatic cancer [95]. The majority of these reports have shown a positive correlation between ALDH1 expression (ALDH1A1 as per [12] ) and metastasis. However, these results should be interpreted with caution due to technical and ethical limitations of working with metastatic tissue, including small numbers of samples analyzed and lack of consistency in staining and scoring methods. For example, diverse grading scales have been used in these studies to score ALDH staining in pathological specimens, including dichotomous scales and continuous scales with diverse cutoff points. This lack of consistency contrasts with the standardized in vivo functional evaluation of ALDH activity using the ALDEFLUORTM assay. In a recent study using matched colon primary tumor and metastases, Fitzgerald et al. reported ALDH1 (ALDH1A1 as per [12] ) as a predictor of poor clinical outcome [94], in direct contrast with an earlier study that had found a negative correlation [120]. In a study that might shed light in this controversy, using nonmatched primary tumor and metastases in colorectal cancer tissues, only homogeneous and intense expression of ALDH1A1 was correlated with metastasis [122]. In addition to ALDH activity/expression in tumor cells, ALDH expression has been recently also been observed in tumor-associated endothelial cells (TEC) from melanoma and oral cancers in vivo. TEC were shown to exhibit increased expression of angiogenic factors and angiogenic behavior in vitro, suggesting that there might be an ALDHmediated CSC activity in the tumor vascular compartment which in turn could promote tumor cell escape to the intravascular space [123]. ALDH in circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) The detection of circulating tumor cells (CTCs) in blood and disseminated tumor cells (DTCs) in bone marrow has been associated with the presence of clinically relevant metastatic disease and poor clinical outcome for a diverse group of solid tumors [124–127]. However, given the high inefficiency of the metastatic cascade, it has been hypothesized that CTCs and/or DTCs may contain sub-populations of cells with enhanced capacity to initiate and maintain growth and give rise to clinically relevant metastases. The biological characteristics and markers of metastasis-initiating CTCs and DTCs are not completely understood. The preclinical and clinical data reviewed above indicate that ALDH is Fig. 1 Molecular mechanisms associated with ALDH in metastasis promotion. The molecular mechanisms underlying the increased tumorigenicity and metastatic capacity of ALDHhi cancer cells involve diverse co-expressed molecular factors and signaling pathways. For example, in breast, ovarian, and pancreatic cancer, ALDH1A1 transcription has been shown to be regulated after binding of C/EBPb, bcatenin, or Smad-4 to the ALDH1A1 promoter sequences (a, b). In breast cancer cells, Notch-induced deacetylation of ALDH1A1 can result in increased CSC capabilities (c). Taken together, these pathways influence downstream functional behaviors such as stem cell-related decisions regarding proliferation and cell fate, epithelial-to-mesenchymal transition, retinoic acid synthesis, hypoxia, DNA damage response, cytokine and RTK signaling activation, and cell migration (d), all of which may contribute to the role of ALDHhi cancer cells in metastasis promotion functionally involved in metastatic activity and is a determinant of cancer clinical outcome, and thus implicate ALDH as a potential biomarker to be assessed in correlation with CTC/DTC activity. To our knowledge, the first attempt to assess ALDH activity in the systemic circulation in correlation with metastasis was published by Jelski et al. [118]. Evaluating serum alcohol dehydrogenase (ADH) and ALDH activity in a small sample of patients with metastatic hepatocarcinoma, this study found a correlation for ADH, but not for ALDH, with metastatic disease. However, early and subsequent attempts at identifying ALDH expression in CTCs/DTCs sub-populations have been successful in breast and endometrial cancer [128–133]. While the scope of these studies is complex given the multi-compartment distribution of CTCs/DTCs, in general they evaluate one or more of the following variables: (i) expression of ALDH in primary tumors in correlation with CTCs/DTCs, (ii) expression of ALDH in CTCs/DTCs as a stem cell marker and its correlation with clinical prognosis and metastatic activity; and/or (iii) co-expression of ALDH with other known markers of stem-like behavior and cancer progression in CTCs/DTCs. Interestingly, the results of these studies are mixed, but this is not surprising given the nascent nature these type of studies, the small cohorts evaluated, the diversity of assays and parameters used to identify and isolate CTCs/DTCs, the inherent technical difficulties of isolating rare cells form clinical samples, and uncertainty about the biological characteristics of clinically relevant CTCs/DTCs that would allow their identification. In one study involving 502 non-metastatic breast cancer patients, although ALDH was expressed in CTCs and DTCs in 14 % of patients in the study cohort, it was not correlated with clinical prognosis or metastasis. In addition, this study showed no correlation of EMT markers in CTCs/DTCs with clinical outcome [134]. In another study, ALDH expression in primary breast tumors was not found to be correlated with the presence of CTCs, although it was correlated with clinical outcome in patients with nonmetastatic disease [135]. In an additional cohort of nonmetastatic breast cancer patients, although ALDH expression in DTCs was correlated with use of neoadjuvant chemotherapy and high tumor grade, it was not associated with metastatic recurrence [130]. Another study in a nonmetastatic breast cancer cohort showed that the CD44? CD24- phenotype in DTCs was a better clinical predictor of cancer progression relative to ALDH expression [136]. In general, studies evaluating ALDH expression in CTCs/ DTCs from patients with early non-metastatic breast cancer have shown less correlation of ALDH in CTCs/DTCs with clinical outcome and metastasis than studies performed in patients with metastatic disease [128, 129]. Therefore, although there is evidence supporting ALDH as a marker of CTC and DTC activity in advanced breast cancer, the functional and clinical implications of ALDH expression in CTCs/DTCs and eventual metastasis in breast cancer patients with early disease remains to be established. This suggests that the use of ALDH in CTCs/DTCs as a risk stratification marker might not be useful in patients with non-advanced disease. However, as described below, important technical considerations involving the methods to enrich CTCs/DTCs might change these results. It is very important to note that in all the studies mentioned above, CTCs/DTCs were enriched using epithelial markers as primary criteria for their isolation. However, there is increasing evidence suggesting that a substantial proportion of CTCs/DTCs might display a more mesenchymal and aggressive phenotype that may not be picked up by standard CTC/DTC assays [124]. In fact, it has been shown that mesenchymal markers are over-expressed in CTCs and DTCs of metastatic and aggressive subtypes of breast cancer [137, 138]. Moreover, ALDH expression in CTCs has been correlated with poor clinical outcome, metastatic progression, and therapy response in patients with metastatic breast cancer [128, 129]. Interestingly, Liu et al. observed that breast CSCs transition between mesenchymal an epithelial states in order to fully develop metastasis, with ALDH participating during the epithelial and more proliferative phase of metastatic colonization in distant tissues. This suggests that ALDH may not be a key marker expressed during the intravascular and more mesenchymal phase of the metastatic cascade [139, 140]. Overall, the study of ALDH as a biomarker for metastasisinitiating cells and clinical outcome in CTCs/DTC is an emerging and promising field of research that is evolving at the pace of the refinement and validation of the technologies used to isolate this important group of cells navigating the metastatic cascade in the systemic circulation. Molecular mechanisms associated with ALDH in metastasis promotion The study of the molecular mechanisms underlying the increased tumorigenicity of ALDHhi cells has revealed diverse co-expressed molecular factors and signaling pathways that might potentially also explain the observed increased metastatic behavior of ALDHhi cancer cells. Since 2007, when the Hedgehog pathway was shown upregulated in ALDHhi pancreatic cancer cells [141], there has been accumulating evidence of signaling pathways associated with ALDHhi cells and their malignant activity (Summarized in Fig. 1). In particular, pathways involved in stem cell proliferation and cell fate [93, 101, 110, 141–147]; EMT [11, 36, 78, 81, 86, 90, 100, 110, 112, 146–155]; retinoic acid pathway [10, 89]; hypoxia [33, 79, 149, 156] and DNA damage responses [143, 157, 158]; cytokine and receptor tyrosine kinase (RTK) [158–160] signaling activation; and cell migration [161], among others, have been implicated in promotion of aggressive behavior in ALDHhi cells. Different isoforms of the Notch receptor have been found to be upregulated in ALDHhi cells from breast cancer, ovarian cancer, lung cancer, and osteosarcoma [81, 89, 100, 144, 145, 147, 148]. In addition, ALDH1A1 has been found to be correlated with Notch expression in lung and breast CSCs [100, 147]. The Wnt-bcatenin pathway has been shown to be activated in cancer cells with high expression of ALDH1A1 and ALDH3A1 in prostate, ovarian, and liver cancer cells [86, 90, 110]; and the TGFb pathway has been reported to facilitate therapy resistance in ALDHhi breast cancer cells, and to be involved in expression of ALDH1A1 in cholangiocarcinoma and pancreatic cancer [90, 103, 151, 152]. Interestingly, for some of these signaling pathways, the evidence suggests dualistic roles in metastasis depending on the cell context. For example, Li et al. reported that ALDH1A1 was involved in lung CSC activity via suppression of the Notch/CDK2/CCNE pathway [101], and, in other study, it was found that Nodal had a tumor suppressor function in ALDHhi cells via the activation of TGFb pathway [150]. It is of note that there is evidence supporting a more complex model of metastasis navigation in which not only the EMT process but also the mesenchymal-to epithelial-transition (MET) processes are both critical for forming clinically relevant metastases [139, 140]. In this regard, research from two independent groups has shown that ALDH may be a marker and potential mechanistic promoter of a more proliferative/epithelial CSC phenotype via MET, while CD44 may, in contrast, be a marker of a more invasive subpopulation of migratory/ mesenchymal CSCs via EMT [78, 146]. In addition, Marcato et al. have reported that ALDH1A3 may have a dual role in breast cancer metastasis promotion depending in the epigenetic cell context through differential retinoic acid signaling [10]. Therapeutic potential of targeting ALDH in metastasis treatment and prevention Although there are relatively few studies assessing the impact of pharmacological or immune targeting of ALDH on metastasis in vivo, the majority of them are consistent in reporting a decrease of metastatic burden after targeting of ALDH. It has been shown that after treatment with the ALDH inhibitors DEAB and the novel A37 compound, there is a decreased metastatic activity in murine models of breast and ovarian cancer [33, 90]. It has also been demonstrated that CSC targeting with ALDH1A1-specific CD8? T cells is followed by decreased spontaneous metastatic burden of HNSCC, pancreatic, and breast cancer cells in vivo [116]. Treatment with RA results in downregulation of ALDH1A1/ALDH3A1 expression or decreased ALDEFLOURTM activity [28, 42, 89], and, in one recent study it has been reported that there is a reduction of in vitro metastatic behavior and reduction of xenograft growth of ovarian cancer cells after RA treatment [89]. However, Marcato et al. have reported that RA treatment has dual effects in a mouse model of human breast cancer metastasis depending on the cell epigenetic context [10]. The small molecule compound disulfiram has been found to display tumor inhibitory activity attributed to different properties, including ALDH1A1 inhibition [35, 162, 163], inhibition of proteasome activity [164, 165], prevention of NF-jB translocation [165, 166], induction of reactive oxygen species generation [167, 168], blockade of the PI3K/PTEN/AKT signaling pathway [169], inactivation of tumor-associated enzymes [170–172], and suppression of metastasis-associated gene expression [170, 171, 173]. Interestingly, it has been reported that disulfiram may have a therapeutic role in the metastatic setting. In one study, cell growth of metastatic osteosarcoma patient-derived cells was significantly decreased after disulfiram treatment in vitro [85]. In another study, cell growth was significantly decreased after disulfiram treatment of a metastatic murine osteosarcoma cell line in vitro [36]. It has also been reported that treatment with this compound decreases spontaneous lung metastatic burden in a syngeneic preclinical model of metastatic murine breast cancer [174]. In addition, a recent Phase IIb clinical trial found that addition of disulfiram to chemotherapy was well tolerated and appears to improve survival in newly diagnosed patients with metastatic non-small cell lung cancer [175]. Currently two clinical trials are evaluating the effect of disulfiram in treating glioblastoma multiforme (NCT01907165 and NCT01777919; www.clinicaltrials.gov). The multiplicity of ALDH isoforms and its widespread tissue/tumor distribution, combined with differential epigenetic landscapes and inconsistency among parameters evaluated in small cohort trials may explain discrepancies observed between preclinical and clinical outcomes. Moreover, selective druggability of different ALDH isoforms is a formidable pharmacological challenge that may also contribute to conflicting results. Physiological concentrations of ALDH are most highly expressed in kidney and liver, which in turn limits the use of nonspecific inhibitors of ALDH that may result in toxic side-effects in patients. In addition, the enzymatic oxidative reaction carried out by different ALDH isoforms is highly nonspecific. For example, the ALDH substrate BAA has been found to be metabolized by different ALDH isoenzymes, including ALDH1A1, 1A2, 1A3, 2, 3A1, and 7 [4, 39, 67, 85]. Thus, there are important biochemical barriers to device a specific ALDH family or isoform inhibitor. Rationalized small molecule discovery has been proposed as a viable methodology to surmount these difficulties and has been successfully employed to target specific aldehyde oxidases of the cytochrome P450 family in cancer cells [176–179]. An array of new generation isoform-specific ALDH inhibitors are under development. Among them, duocarmycin analogues stand out due to their ultra-high alkylating potency and additional ability to specifically target ALDH1A1 [12]. Therefore, it is expected that novel, potent, and isoform-specific ALDH inhibitors could enter the pipeline of experimental and clinical assessment in cancer therapy in the coming years. Taken together, these results underscore the potential of ALDH as a therapeutic target against metastasis. Conclusions and future perspectives Tumors are heterogeneous at the genetic, epigenetic, and tumorigenic level. There is substantial evidence indicating that tumor cells with stem-like capabilities are responsible, at least in part, for heterogeneity at the tumorigenic and metastatic level. ALDH stands out among the expansive and diverse group of CSC markers because of its widespread association with different types of solid tumors and the multiplicity of its biological functions, including retinoic acid signaling, antioxidant protection, osmoregulation, drug metabolism, and structural support. However, validation of ALDH as a prognostic biomarker and/or therapeutic target in the clinical setting has not yet come fully to fruition. Moving forward, it is critical that future studies include better standardization of ALDH identification and scoring methods, patient characteristics, and cohort sizes. In addition, more attention must be drawn to the study of the therapeutic effects of ALDH isoenzyme inhibitors in CTCs, DTCs, and metastatic and migratory activity. We believe that only a consistent preclinical and clinical approach revolving around CSC-mediated metastasis and therapy resistance will reveal the therapeutic and biomarker potential of ALDH in solid tumors. In conclusion, it is clear that ALDH is not only a marker for aggressive stem-like and metastatic cells, but that it is also mechanistically involved in these behaviors. Hence, the study of ALDH as a biomarker and functional mediator of metastasis in vivo is a promissory field for discovering targets that might interfere with solid tumor progression. However, with the heterogeneity of ALDH isoforms described as CSC markers in different tumor types, and the newly described cell context dependent tumorigenic function of ALDH, it is likely that different isoforms may contribute differently to metastasis in different types of solid tumors. Moreover, given that it has been shown that other isoenzymes besides ALDH1A1 and ALDH1A3 are responsible for the activity reported in the ALDEFLUORTM assay, and the experimental evidence supporting multi-enzyme isoform participation in the same tumor, it is also likely that more than one ALDH isoform may be contributing to progression within the same tumor. Continued intensive investigation into the functional contribution of ALDH to cancer progression and metastasis will be important for tackling the enormous therapeutic challenge that such diverse landscape imposes. Acknowledgments We thank members of our laboratory and our collaborators for their research work and helpful discussions. The authors’ research on ALDH and CSCs is supported by research grants from the Canadian Breast Cancer Foundation (Ontario Region) and donor support from John and Donna Bristol and Richard and Susanne Shaftoe through the London Health Sciences Foundation (to ALA). MR-T is the recipient of a Vanier Doctoral Scholarship from the Canadian Institutes of Health Research (CIHR). ALA is supported by a CIHR New Investigator Award and an Early Researcher Award from the Ontario Ministry of Research and Innovation. Compliance with ethical standards Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://crea tivecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. o ]4 tc 1 a 15 i o 1. Redig A , McAllister S ( 2013 ) Breast cancer as a systemic dis- ease: a view of metastasis . J Internal Med 274 ( 2 ): 113 - 126 2. Chambers AF , Groom AC , MacDonald IC ( 2002 ) Metastasis: Rev Cancer 2 ( 8 ): 563 - 572 3. Lu J , Steeg PS , Price JE , Krishnamurthy S , Mani SA , Reuben J , Cristofanilli M , Dontu G , Bidaut L , Valero V ( 2009 ) Breast 69 ( 12 ): 4951 - 4953 4. Luzzi KJ , MacDonald IC , Schmidt EE , Kerkvliet N , Morris VL , Chambers AF , Groom AC ( 1998 ) Multistep nature of metastatic J Pathol 153 ( 3 ): 865 - 873 5. Ma I , Allan AL ( 2011 ) The role of human aldehyde dehydro- 7 ( 2 ): 292 - 306 6. Beck B , Blanpain C ( 2013 ) Unravelling cancer stem cell potential. Nat Rev Cancer 13 ( 10 ): 727 - 738 7. Croker AK , Goodale D , Chu J , Postenka C , Hedley BD , Hess DA , Allan AL ( 2009 ) High aldehyde dehydrogenase and Med 13 ( 8B ): 2236 - 2252 8. Charafe-Jauffret E , Ginestier C , Iovino F , Wicinski J , Cervera D , Wicha MS ( 2009 ) Breast cancer cell lines contain functional molecular signature . Cancer Res 69 ( 4 ): 1302 - 1313 9. Marcato P , Dean CA , Pan D , Araslanova R , Gillis M , Joshi M , PW ( 2011 ) Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis . Stem Cells 29 ( 1 ): 32 - 45 10. Marcato P , Dean CA , Liu RZ , Coyle KM , Bydoun M , Wallace mantonio CA , Mackey JR , Godbout R , Lee PW ( 2015 ) Alde- hyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling . Mol Oncol 9 ( 1 ): 17 - 31 11. van den Hoogen C , van der Horst G , Cheung H , Buijs JT , Pelger RC , van der Pluijm G ( 2011 ) The aldehyde dehydrogenase enzyme 7A1 is functionally involved in prostate cancer bone metastasis. Clin Exp Metastasis 28 ( 7 ): 615 - 625 12. Pors K , Moreb JS ( 2014 ) Aldehyde dehydrogenases in cancer: Discov Today 19 ( 12 ): 1953 - 1963 13. Alison MR , Guppy NJ , Lim SM , Nicholson LJ ( 2010 ) Finding J Pathol 222 ( 4 ): 335 - 344 14. Vasiliou V , Thompson DC , Smith C , Fujita M , Chen Y ( 2013 ) disease and cancer stem cells . Chem Biol Interact 202 ( 1-3 ): 2 - 10 15. Charafe-Jauffret E , Ginestier C , Iovino F , Tarpin C , Diebel M , Viens P , Wicha MS ( 2010 ) Aldehyde dehydrogenase 1-positive in inflammatory breast cancer . Clin Cancer Res 16 ( 1 ): 45 - 55 16. Koppaka V , Thompson DC , Chen Y , Ellermann M , Nicolaou KC , ( 2012 ) Aldehyde dehydrogenase inhibitors: a comprehensive specificity, and clinical application . Pharmacol Rev 64 ( 3 ): 520 - 539 17. Mitchell DY , Petersen DR ( 1987 ) The oxidation of a-b unsat- aldehyde dehydrogenases . Toxicol Appl Pharm 87 ( 3 ): 403 - 410 18. Lindahl R , Petersen DR ( 1991 ) Lipid aldehyde oxidation as a physiological role for class 3 aldehyde dehydrogenases . Bio- chem Pharm 41 ( 11 ): 1583 - 1587 19. Singh S , Brocker C , Koppaka V , Chen Y , Jackson BC , Mat- sumoto A , Thompson DC , Vasiliou V ( 2013 ) Aldehyde dehy- Free Radic Biol Med 56 : 89 - 101 20. Coyle K , Sultan M , Thomas M , Vaghar-Kashani A , Marcato P ( 2013 ) Retinoid signaling in cancer and its promise for therapy . J Carcinog Mutagen S 7: 16 - 18 21. Januchowski R , Wojtowicz K , Zabel M ( 2013 ) The role of Biomed Pharm 67 ( 7 ): 669 - 680 22. Marchitti SA , Brocker C , Stagos D , Vasiliou V ( 2008 ) Non- P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4 ( 6 ): 697 - 720 23. Chute JP , Muramoto GG , Whitesides J , Colvin M , Safi R , Chao NJ , McDonnell DP ( 2006 ) Inhibition of aldehyde dehydrogenase and stem cells . Proc Nat Acad Sci USA 103 ( 31 ): 11707 - 11712 24. Tonge PD , Andrews PW ( 2010 ) Retinoic acid directs neuronal autonomous manner . Differentiation 80 ( 1 ): 20 - 30 25. Z-y Su , Li Y , X-l Zhao , Zhang M ( 2010 ) All-trans retinoic acid 11 ( 7 ): 489 - 496 26. Simandi Z , Balint BL , Poliska S , Ruhl R , Nagy L ( 2010 ) embryonic stem cells in embryoid bodies . FEBS Lett 584(14): 3123- 3130 27. Ren M , Pozzi S , Bistulfi G , Somenzi G , Rossetti S , Sacchi N ( 2005 ) Impaired retinoic acid (RA) signal leads to RARb2 25 ( 23 ): 10591 - 10603 28. Croker AK , Allan AL ( 2012 ) Inhibition of aldehyde dehydro- resistance of stem-like ALDHhiCD44(?) human breast cancer cells. Breast Cancer Res Treat 133 ( 1 ): 75 - 87 29. Li X , Wan L , Geng J , Wu C-L , Bai X ( 2012 ) Aldehyde dehy- drogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome . J Thoracic Oncol 7 ( 8 ): 1235 - 1245 30. Moreb JS , Baker HV , Chang LJ , Amaya M , Lopez MC , Ostmark B , Chou W ( 2008 ) ALDH isozymes downregulation affects cell Mol Cancer 7 : 87 31. Kakizuka A , Miller W , Umesono K , Warrell R , Frankel S , Murty V , Dmitrovsky E , Evans R ( 1991 ) Chromosomal translocation t ( 15 ; 17) in human acute promyelocytic leukemia Cell 66 ( 4 ): 663 - 674 32. de The´ H, Lavau C , Marchio A , Chomienne C , Degos L , Dejean A ( 1991 ) The PML-RARa fusion mRNA generated by the t ( 15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66 ( 4 ): 675 - 684 33. Kim R -J, Park J-R , Roh K-J , Choi A-R , Kim S-R , Kim P-H , Yu JH , Lee JW , Ahn S-H , Gong G ( 2013 ) High aldehyde dehy- cells by activating hypoxia-inducible factor-2a . Cancer Lett 333 ( 1 ): 18 - 31 34. Mizuno T , Suzuki N , Makino H , Furui T , Morii E , Aoki H, Kunisada T , Morishige K ( 2015 ) Cancer stem-like cells of reactive oxygen species . Gynecol Oncol 137 ( 2 ): 299 - 305 35. Liu P , Brown S , Goktug T , Channathodiyil P , Kannappan V , Hugnot J , Guichet P , Bian X , Armesilla A , Darling J ( 2012 ) cer 107 ( 9 ): 1488 - 1497 36. Mu X , Isaac C , Schott T , Huard J , Weiss K ( 2013 ) Rapamycin potential in murine osteosarcoma cells . Sarcoma 2013 : 480713 37. Vasiliou V , Nebert DW ( 2005 ) Analysis and update of the Genom 2 ( 2 ): 138 38. Jean E , Laoudj-Chenivesse D , Notarnicola C , Rouger K , Ser- ( 2011 ) Aldehyde dehydrogenase activity promotes survival of human muscle precursor cells . J Cell Mol Med 15 ( 1 ): 119 - 133 39. Kitahara O , Katagiri T , Tsunoda T , Harima Y , Nakamura Y ( 2002 ) Classification of sensitivity or resistance of cervical 62 genes selected by cDNA microarray analysis . Neoplasia 4 ( 4 ): 295 - 303 40. Sladek NE , Kollander R , Sreerama L , Kiang DT ( 2002 ) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) chemotherapeutic regimens . Cancer Chemother Pharmacol 49 (4 ): 309 - 321 41. Russo JE , Hilton J ( 1988 ) Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells . Cancer Res 48 ( 11 ): 2963 - 2968 42. Moreb JS , Gabr A , Vartikar GR , Gowda S , Zucali JR , Mohuczy D ( 2005 ) Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde . J Pharmacol Exper Ther 312 ( 1 ): 339 - 345 43. Moreb J , Zucali J , Zhang Y , Colvin M , Gross M ( 1992 ) Role of progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1b and tumor necrosis factor . Cancer Res 52 ( 7 ): 1770- 1774 44. Honoki K , Fujii H , Kubo A , Kido A , Mori T , Tanaka Y , Tsu- jiuchi T ( 2010 ) Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24 ( 2 ): 501 - 505 45. Landen CN , Goodman B , Katre AA , Steg AD , Nick AM , Stone RL , Miller LD , Mejia PV , Jennings NB , Gershenson DM ( 2010 ) cancer. Mol Cancer Ther 9 ( 12 ): 3186 - 3199 46. Kawasoe M , Yamamoto Y , Okawa K , Funato T , Takeda M , Hara T , Tsurumi H , Moriwaki H , Arioka Y , Takemura M ( 2013 ) the upregulation of aldehyde dehydrogenase 1 family member A2. Exp Hematol 41 ( 7 ): 597 - 603 e592 47. Lee DH , Chung K , Song J-A , T-h Kim , Kang H, Huh JH , S-g Jung , Ko JJ , An HJ ( 2010 ) Proteomic identification of pacli- taxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells . J Proteome Res 9 ( 11 ): 5668 - 5676 48. Stewart M , Malek K , Crabb DW ( 1996 ) Distribution of mes- senger RNAs for aldehyde dehydrogenase 1, aldehyde dehy- drogenase 2, and aldehyde dehydrogenase 5 in human tissues . J Investig Med 44 ( 2 ): 42 - 46 49. Dipple K , Crabb D ( 1993 ) The mitochondrial aldehyde dehy- tissue-specific manner . Biochem Biophys Res Commun 193 ( 1 ): 420- 427 50. Storms RW , Trujillo AP , Springer JB , Shah L , Colvin OM , Ludeman SM , Smith C ( 1999 ) Isolation of primitive human nase activity . Proc Nat Acad of Sci USA 96 ( 16 ): 9118 - 9123 51. Corti S , Locatelli F , Papadimitriou D , Donadoni C , Salani S , Del Bo R , Strazzer S , Bresolin N , Comi GP ( 2006 ) Identification of a aldehyde dehydrogenase activity . Stem Cells 24 ( 4 ): 975 - 985 52. Ginestier C , Hur MH , Charafe-Jauffret E , Monville F , Dutcher J , Hayes D , Birnbaum D , Wicha MS , Dontu G ( 2007 ) ALDH1 is a 1 ( 5 ): 555 - 567 53. Pearce DJ , Bonnet D ( 2007 ) The combined use of Hoechst 35 ( 9 ): 1437 - 1446 54. Levi BP , Yilmaz O ¨ H, Duester G , Morrison SJ ( 2009 ) Aldehyde dehydrogenase 1a1 is dispensable for stem cell function in the mouse hematopoietic and nervous systems . Blood 113 ( 8 ): 1670 - 1680 55. Muramoto GG , Russell JL , Safi R , Salter AB , Himburg HA , Daher P , Meadows SK , Doan P , Storms RW , Chao NJ ( 2010 ) stem cells with radioprotective capacity . Stem Cells 28 ( 3 ): 523- 534 56. Armstrong L , Stojkovic M , Dimmick I , Ahmad S , Stojkovic P , Hole N , Lako M ( 2004 ) Phenotypic characterization of murine aldehyde dehydrogenase activity . Stem Cells 22 ( 7 ): 1142 - 1151 57. Zhuang X , Zhang W , Chen Y , Han X , Li J , Zhang Y , Zhang Y , Zhang S , Liu B ( 2012 ) Doxorubicin-enriched, ALDHbr mouse virus type 1. BMC Cancer 12 ( 1 ): 549 58. Wang SH , Lu L , Fan Y , Wicha MS , Cao Z , Chang AE , J-c Xia, Baker JR Jr, Li Q ( 2014 ) Characterization of a novel transgenic mouse tumor model for targeting HER2? cancer stem cells . Int J Biol Sci 10 ( 1 ): 25 59. Vaidyanathan G , Song H , Affleck D , McDougald DL , Storms RW , Zalutsky MR , Chin BB ( 2009 ) Targeting aldehyde dehy- 36 ( 8 ): 919 - 929 60. Huang EH , Hynes MJ , Zhang T , Ginestier C , Dontu G , Appel- man H , Fields JZ , Wicha MS , Boman BM ( 2009 ) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colon tumorigenesis . Cancer Res 69 ( 8 ): 3382 - 3389 61. Isfoss BL , Holmqvist B , Jernstro¨m H , Alm P , Olsson H ( 2013 ) ductules. BMC Clin Pathol 13 ( 1 ): 28 62. Khoury T , Ademuyiwa FO , Chandraseekhar R , Jabbour M , DeLeo A , Ferrone S , Wang Y , Wang X ( 2012 ) Aldehyde dehydrogenase 1A1 expression in breast cancer is associated chemotherapy. Mod Pathol 25 ( 3 ): 388 - 397 63. Moreb JS , Ucar D , Han S , Amory JK , Goldstein AS , Ostmark B , Chang LJ ( 2012 ) The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected Chem Biol Interact 195 ( 1 ): 52 - 60 64. Marcato P , Dean CA , Giacomantonio CA , Lee PW ( 2011 ) comes down to the specific isoform . Cell Cycle 10 ( 9 ): 1378 - 1384 65. Luo Y , Dallaglio K , Chen Y , Robinson WA , Robinson SE , ( 2012 ) ALDH1A isozymes are markers of human melanoma 30 ( 10 ): 2100 - 2113 66. Xia P ( 2014 ) Surface markers of cancer stem cells in solid tumors. Curr Stem Cell Res Ther 9 ( 2 ): 102 - 111 67. Tirino V , Desiderio V , Paino F , De Rosa A , Papaccio F , La Noce M , Laino L , De Francesco F , Papaccio G ( 2013 ) Cancer their isolation and characterization . FASEB 27 ( 1 ): 13 - 24 68. Fabian A , Vereb G , Szo¨llo}si J ( 2013 ) The hitchhikers guide to A 83 ( 1 ): 62 - 71 69. Keysar SB , Jimeno A ( 2010 ) More than markers: biological Ther 9 ( 9 ): 2450 - 2457 70. Visvader JE , Lindeman GJ ( 2008 ) Cancer stem cells in solid Rev Cancer 8 ( 10 ): 755 - 768 71. Pouliot N , Pearson HB , Burrows A ( 2000 ) Investigating 2000. http://www.ncbi.nlm.nih.gov/books/NBK100379/ 72. Brooks SA , Schumacher U ( 2001 ) Metastasis research protocols, vol 58. Springer, Berlin 73. Grimshaw MJ , Cooper L , Papazisis K , Coleman JA , Bohnen- JM ( 2008 ) Mammosphere culture of metastatic breast cancer Res 10 ( 3 ): R52 74. Sorita˘u O , Tomuleasa C , Pall E , Vira´g P , Fischer-Fodor E , Foris V ( 2010 ) Enhanced chemoresistance and tumor sphere formation as a ovarian cancer . Rom J Morphol Embryol 51 ( 2 ): 259 - 264 75. Cioce M , Gherardi S , Viglietto G , Strano S , Blandino G , Muti P , Ciliberto G ( 2010 ) Mammosphere-forming cells from breast early progenitor-targeting drugs . Cell Cycle 9 ( 14 ): 2950 - 2959 76. Kerbel R , Kobayashi H , Graham CH ( 1994 ) Intrinsic or acquired J Cell Biochem 56 ( 1 ): 37 - 47 77. Wong ST , Goodin S ( 2009 ) Overcoming drug resistance in patients with metastatic breast cancer . Pharmacotherapy 29 ( 8 ): 954- 965 78. Liu S , Cong Y , Wang D , Sun Y , Deng L , Liu Y , Martin-Trevino Birnbaum D , Wong ST , Zhan M , Chang JC , Wicha MS ( 2014 ) Cell Rep 2 ( 1 ): 78 - 91 79. Liao J , Qian F , Tchabo N , Mhawech-Fauceglia P , Beck A , Qian Z , Wang X , Huss WJ , Lele SB , Morrison CD ( 2014 ) Ovarian through hypoxia-resistant metabolism . PLoS One 9 ( 1 ): e84941 80. Kuroda T , Hirohashi Y , Torigoe T , Yasuda K , Takahashi A , T , Sato N ( 2013 ) ALDH1-high ovarian cancer stem-like cells and ALDH1 high expression is associated with poor prognosis . PLoS One 8 ( 6 ): e65158 81. Mu X , Isaac C , Greco N , Huard J , Weiss K ( 2013 ) Notch sig- 3 : 143 82. Ajani J , Wang X , Song S , Suzuki A , Taketa T , Sudo K , Wadhwa R , Hofstetter W , Komaki R , Maru D ( 2014 ) ALDH-1 expression 8 ( 1 ): 142 - 149 83. Reeves K , van der Pluijm G , Cecchini M , Eaton C , Hamdy F , Brown N ( 2013 ) The influence of tumour aldehyde dehydroge- of the physiological society , 2013 . The Physiological Society 84. Tanei T , Morimoto K , Shimazu K , Kim SJ , Tanji Y , Taguchi T , Tamaki Y , Noguchi S ( 2009 ) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with chemotherapy for breast cancers . Clin Cancer Res 15 ( 12 ): 4234- 4241 85. Greco N , Schott T , Mu X , Rothenberg A , Voigt C , McGough RL 3rd , Goodman M , Huard J , Weiss KR ( 2014 ) ALDH activity J Cancer Ther 5 ( 4 ): 331 - 338 86. Cojoc M , Peitzsch C , Kurth I , Trautmann F , Kunz-Schughart ( 2015 ) Aldehyde dehydrogenase is regulated by b- Catenin/TCF Cancer Res 75 ( 7 ): 1482 - 1494 87. Charafe-Jauffret E , Ginestier C , Bertucci F , Cabaud O , Wicinski (2013) ALDH1-positive cancer stem cells predict engraftment of program. Cancer Res 73 ( 24 ): 7290 - 7300 88. Li D , Zhang T , Gu W , Li P , Cheng X , Tong T , Wang W ( 2015 ) The ALDH1? subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics . Oncol Rep 33 ( 5 ): 2291 - 2298 89. Young M-J , Wu Y-H , Chiu W-T , Weng T-Y , Huang Y-F , Chou C-Y ( 2015 ) All-trans retinoic acid downregulates ALDH1-me- cells. Carcinogenesis 36 : 498 - 507 bgv018 90. Condello S , Morgan C, Nagdas S , Cao L , Turek J , Hurley T , Matei D ( 2015 ) b-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids . Oncogene 34 ( 18 ): 2297 - 2308 91. Choi SA , Lee JY , Phi JH , Wang K-C , Park C-K , Park S-H , Kim S-K ( 2014 ) Identification of brain tumour initiating cells using 50 ( 1 ): 137 - 149 92. Soehngen E , Schaefer A , Koeritzer J , Huelsmeyer V , Zimmer C , Ringel F , Gempt J , Schlegel J ( 2014 ) Hypoxia upregulates aldehyde dehydrogenase isoform 1 (ALDH1) expression and toma cells . Brain Tumor Pathol 31 ( 4 ): 247 - 256 93. Yu C-C , Lo W-L , Chen Y-W , Huang P-I , Hsu H-S , Tseng L-M , Hung S-C , Kao S-Y , Chang C-J , Chiou SH ( 2010 ) Bmi-1 reg- and neck squamous cancer-derived ALDH1 positive cells . J Oncol 2011 94. Fitzgerald TL , Rangan S , Dobbs L , Starr S , Sigounas G ( 2014 ) The impact of Aldehyde dehydrogenase 1 expression on prog- nosis for metastatic colon cancer . J Surg Res 192 ( 1 ): 82 - 89 95. James MI , Howells LM , Karmokar A , Higgins JA , Greaves P , Cai H , Dennison A , Metcalfe M , Garcea G , Lloyd DM ( 2015 ) a cautionary note . PLoS One 10 ( 2 ): e0117776 96. Larzabal L , El-Nikhely N , Redrado M , Seeger W , Savai R , Calvo A ( 2013 ) Differential effects of drugs targeting cancer tumors and metastasis . PLoS One 8 ( 11 ): e79798 97. Liang D , Shi Y ( 2012 ) Aldehyde dehydrogenase-1 is a specific Oncol 29 ( 2 ): 633 - 639 98. Akunuru S , Zhai QJ , Zheng Y ( 2012 ) Non-small cell lung cancer 3 ( 7 ): e352 99. Lin J , Liu X , Ding D ( 2015 ) Evidence for epithelial-mes- 8 ( 1 ): 847 100. Sullivan JP , Spinola M , Dodge M , Raso MG , Behrens C , Gao B , Schuster K , Shao C , Larsen JE , Sullivan LA ( 2010 ) Aldehyde 70 ( 23 ): 9937 - 9948 101. Li Z , Xiang Y , Xiang L , Xiao Y , Li F , Hao P ( 2014 ) ALDH the Notch/CDK2/CCNE pathway. PLoS One 9 ( 3 ): e92669 102. Yang L , Ren Y , Yu X , Qian F , Bian BS , Xiao HL , Wang WG , K , Qian C , Zhang X , Zhang P , Cui YH , Bian XW ( 2014 ) ALDH1A1 defines invasive cancer stem-like cells and predicts cinoma. Mod Pathol 27 ( 5 ): 775 - 783 103. Hoshino Y , Nishida J , Katsuno Y , Koinuma D , Aoki T , Kokudo N , Miyazono K , Ehata S ( 2015 ) Smad4 decreases the population repression of ALDH1A1 . Am J Pathol 185 ( 5 ): 1457 - 1470 104. Wang K , Chen X , Zhan Y , Jiang W , Liu X , Wang X , Wu B ( 2013 ) Increased expression of ALDH1A1 protein is associated Oncol 30 ( 2 ): 1 - 9 105. Huang C-P , Tsai M-F , Chang T -H, Tang W-C , Chen S-Y , Lai H-H , Lin T-Y , Yang JC-H , Yang P-C , Shih J-Y ( 2013 ) ALDH- 328 ( 1 ): 144 - 151 106. Yue L , Huang Z-M , Fong S , Leong S , Jakowatz JG , Charruyer- Reinwald A , Wei M , Ghadially R ( 2015 ) Targeting ALDH1 to anoma. Melanoma Res 25 ( 2 ): 138 - 148 107. Jia J , Parikh H , Xiao W , Hoskins JW , Pflicke H , Liu X , Collins Petersen GM , Amundadottir LT ( 2013 ) An integrated tran- gene for pancreatic cancer . BMC Med Genomics 6 : 33 108. Mao P , Joshi K , Li J , Kim S-H , Li P , Santana-Santos L , Luthra S , Chandran UR , Benos PV , Smith L ( 2013 ) Mesenchymal bolism involving aldehyde dehydrogenase 1A3 . Proc Nat Acad Sci 110 ( 21 ): 8644 - 8649 109. Yan J , De Melo J , Cutz J , Aziz T , Tang D ( 2014 ) Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis . Br J Cancer 110 ( 10 ): 2593 - 2603 110. Calderaro J , Nault J-C , Bioulac-Sage P , Laurent A , Blanc J-F , Decaens T , Zucman-Rossi J ( 2014 ) ALDH3A1 is overexpressed of the Wnt/ß-catenin pathway . Virchows Arch 464 ( 1 ): 53 - 60 111. Fillmore CM , Kuperwasser C ( 2008 ) Human breast cancer cell Cancer Res 10 ( 2 ): R25 112. Rasheed ZA , Yang J , Wang Q , Kowalski J , Freed I , Murter C , Hong S-M , Koorstra J-B , Rajeshkumar N , He X ( 2010 ) Prognostic sig- creatic adenocarcinoma . J Nat Cancer Inst 102 ( 5 ): 340 - 351 113. van den Hoogen C , van der Horst G , Cheung H , Buijs JT , Pelger RC , van der Pluijm G ( 2011 ) Integrin av expression is required type in human prostate cancer . Am J Pathol 179 ( 5 ): 2559 - 2568 114. van den Hoogen C , van der Horst G , Cheung H , Buijs JT , Lippitt Cecchini MG , Pelger RC , van der Pluijm G ( 2010 ) High alde- 70 ( 12 ): 5163 - 5173 115. Sun S , Wang Z ( 2010 ) ALDH high adenoid cystic carcinoma cells ating metastasis . Biochem Biophys Res Commun 396 ( 4 ): 843 - 848 116. Visus C , Wang Y , Lozano-Leon A , Ferris RL , Silver S , S ( 2011 ) Targeting ALDHbright Human Carcinoma-Initiating Cells with ALDH1A1-Specific CD8? T Cells . Clin Cancer Res 17 ( 19 ): 6174 - 6184 117. Marselos M , Michalopoulos G ( 1987 ) Changes in the pattern of adenocarcinomas of the human colon . Cancer Lett 34 ( 1 ): 27 - 37 118. Jelski W , Zalewski B , Szmitkowski M ( 2008 ) Alcohol dehy- Lab Anal 22 ( 3 ): 204 - 209 119. Shao J , C-p Pan , Wang M- w Wu , X-h Ma B ( 2013 ) Discordance of aldehyde dehydrogenase 1 and estrogen receptor expression Anat Sin 2 : 224 - 228 120. Hessman CJ , Bubbers EJ , Billingsley KG , Herzig DO , Wong MH ( 2012 ) Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage col- orectal cancer . Am J Surg 203 ( 5 ): 649 - 653 121. Sreerama L , Sladek NE ( 1997 ) Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-me- Res 3 ( 11 ): 1901 - 1914 122. Vogler T , Kriegl L , Horst D , Engel J , Sagebiel S , Scha¨ffauer AJ , Kirchner T , Jung A ( 2012 ) The expression pattern of aldehyde dehydrogenase 1 (ALDH1) is an independent prognostic marker 92 ( 1 ): 111 - 117 123. Ohmura-Kakutani H , Akiyama K , Maishi N , Ohga N , Hida Y , ( 2014 ) Identification of tumor endothelial cells with high alde- PLoS One 9 ( 12 ): e113910 124. Lowes LE , Allan AL ( 2014 ) Recent advances in the molecular characterization of circulating tumor cells . Cancers 6 ( 1 ): 595 - 624 125. Giuliano M , Giordano A , Jackson S , De Giorgi U , Mego M , Cohen EN , Gao H , Anfossi S , Handy BC , Ueno NT ( 2014 ) Breast Cancer Res 16 ( 5 ): 440 126. Baccelli I , Schneeweiss A , Riethdorf S , Stenzinger A , Schillert A , Vogel V , Klein C , Saini M , Ba¨uerle T , Wallwiener M ( 2013 ) graft assay . Nat Biotechnol 31 ( 6 ): 539 - 544 127. Bednarz-Knoll N , Alix-Panabie`res C , Pantel K ( 2011 ) Clinical Res 13 ( 6 ): 228 128. Aktas B , Tewes M , Fehm T , Hauch S , Kimmig R , Kasimir- Bauer S ( 2009 ) Stem cell and epithelial-mesenchymal transition 11 ( 4 ): R46 129. Gradilone A , Naso G , Raimondi C , Cortesi E , Gandini O , fanilli M ( 2011 ) Circulating tumor cells (CTCs) in metastatic characterization. Ann Oncol 22 ( 1 ): 86 - 92 130. Reuben JM , Lee BN , Gao H , Cohen EN , Mego M , Giordano A , fanilli M , Lucci A , Woodward WA ( 2011 ) Primary breast cancer and CD44(?)CD24lo cancer stem cell phenotype . Eur J Cancer 47 ( 10 ): 1527 - 1536 131. Theodoropoulos PA , Polioudaki H , Agelaki S , Kallergi G , Saridaki Z , Mavroudis D , Georgoulias V ( 2010 ) Circulating blood of patients with breast cancer . Cancer Lett 288 ( 1 ): 99 - 106 132. Zirvi KA , Hill GJ , Hill HZ ( 1986 ) Comparative studies of Oncol 31 ( 2 ): 123 - 126 133. Alonso-Alconada L , Muinelo-Romay L , Madissoo K , Diaz- Coenegrachts L , Cano A ( 2014 ) Molecular profiling of circu- endometrial cancer . Mol Cancer 13 ( 1 ): 223 134. Krawczyk N , Meier-Stiegen F , Banys M , Neubauer H , Ruck- haeberle E , Fehm T ( 2014 ) Expression of stem cell and cells of breast cancer patients . Biomed Res Int 2014 : 415721 135. Woodward WA , Krishnamurthy S , Lodhi A , Xiao L , Gong Y , Cristofanilli M , Buchholz TA , Lucci A ( 2014 ) Aldehyde dehy- drogenase1 immunohistochemical staining in primary breast cells. J Cancer 5 ( 5 ): 360 136. Giordano A , Gao H , Cohen E , Anfossi S , Khoury J , Hess K , Krishnamurthy S , Tin S , Cristofanilli M , Hortobagyi G ( 2013 ) breast cancer patients . Ann Oncol: mdt223 137. Papadaki MA , Kallergi G , Zafeiriou Z , Manouras L , Theodor- opoulos PA , Mavroudis D , Georgoulias V , Agelaki S ( 2014 ) Co- with early and metastatic breast cancer . BMC Cancer 14 ( 1 ): 651 138. Giordano A , Gao H , Anfossi S , Cohen E , Mego M , Lee B-N , Tin S , De Laurentiis M , Parker CA , Alvarez RH ( 2012 ) Epithelial- HER2-positive metastatic breast cancer . Mol Cancer Ther 11 ( 11 ): 2526 - 2534 139. Tsai JH , Donaher JL , Murphy DA , Chau S , Yang J ( 2012 ) 22 ( 6 ): 725 - 736 140. Ocan˜a OH , Co´ rcoles R , Fabra A´ , Moreno-Bueno G , Acloque H , Vega S , Barrallo-Gimeno A , Cano A , Nieto MA ( 2012 ) Meta- mesenchymal transition inducer Prrx1 . Cancer Cell 22 ( 6 ): 709- 724 141. Feldmann G , Dhara S , Fendrich V , Bedja D , Beaty R , Mullen- ( 2007 ) Blockade of hedgehog signaling inhibits pancreatic tion therapy in solid cancers . Cancer Res 67 ( 5 ): 2187 - 2196 142. Ozbek E , Calik G , Otunctemur A , Aliskan T , Cakir S , Dursun M, Somay A ( 2012 ) Stem cell markers aldehyde dehydrogenase type 1 and nestin expressions in renal cell cancer . Archivio italiano di urologia , andrologia 84 ( 1 ): 7 - 11 143. Meng E , Mitra A , Tripathi K , Finan MA , Scalici J , McClellan S , da Silva LM , Reed E , Shevde LA , Palle K ( 2014 ) ALDH1A1 signaling. PLoS One 9 ( 9 ): e107142 144. Suman S , Das T , Damodaran C ( 2013 ) Silencing NOTCH sig- breast cancer cells . Br J Cancer 109 ( 10 ): 2587 - 2596 145. D'Angelo RC , Ouzounova M , Davis A , Choi D , Tchuenkam ( 2015 ) Notch reporter activity in breast cancer cell lines iden- 14 ( 3 ): 779 - 787 146. Chen X , Lingala S , Khoobyari S , Nolta J , Zern MA , Wu J ( 2011 ) Epithelial mesenchymal transition and hedgehog sig- invasion of hepatoma subpopulations . J Hepatol 55 ( 4 ): 838 - 845 147. Zhao D , Mo Y , Li M-T , Zou S-W , Cheng Z-L , Sun Y-P , Xiong Y , Guan K-L , Lei Q-Y ( 2014 ) NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Investig 124 ( 12 ): 5453 - 5465 148. Cui J , Li P , Liu X , Hu H , Wei W ( 2015 ) Abnormal expression of ALDHhiCD44? cells correlates highly with Ki-67 expression in breast cancer . Oncol Lett 9 ( 4 ): 1600 - 1606 149. Tiezzi DG , Clagnan WS , Mandarano LRM , de Sousa CB , Marana HRC , Tiezzi MG , de Andrade JM ( 2013 ) Expression of associated with expression of hypoxia-inducible factors 1 and 2 Clinics 68 ( 5 ): 592 - 598 150. Wang Y , Jiang Y , Tian T , Hori Y , Wada N , J-i Ikeda, Morii E ( 2013 ) Inhibitory effect of Nodal on the expression of aldehyde dehydrogenase 1 in endometrioid adenocarcinoma of uterus . Biochem Biophys Res Comm 440 ( 4 ): 731 - 736 151. Shuang Z-Y , Wu W-C , Xu J , Lin G , Liu Y-C , Lao X-M , Zheng L , Li S ( 2014 ) Transforming growth factor-b1-induced epithe- 354 ( 2 ): 320 - 328 152. Bhola NE , Balko JM , Dugger TC , Kuba MG , Sa´nchez V , San- ders M , Stanford J , Cook RS , Arteaga CL ( 2013 ) TGF-b inhi- breast cancer . J Clin Invest 123 ( 3 ): 1348 153. Wei L , Liu T-T , Wang H-H , Hong H-M , Yu AL , Feng H-P , Chang W-W ( 2011 ) Hsp27 participates in the maintenance of Res 13 ( 5 ): R101 154. Lee D , Lee JW ( 2015 ) Self-renewal and circulating capacities of between TM4SF5 and CD44 . BMB Rep 48 ( 3 ): 127 155. Qian X , Anzovino A , Kim S , Suyama K , Yao J , Hulit J , Agiostratidou G , Chandiramani N , McDaid H , Nagi C ( 2014 ) N- Oncogene 33 ( 26 ): 3411 - 3421 156. Taiseer I , Samar AR , Abdelmonem H ( 2014 ) Immunohisto- chemical Expression of Aldehyde Dehydrogenase-1 and Hypoxia- Inducible Factor-1 alpha in Breast Cancer . Int J Adv Res 2 ( 7 ): 822 - 830 157. Serrano D , Bleau A-M , Fernandez-Garcia I , Fernandez-Marcelo T , Iniesta P , Ortiz-de-Solorzano C , Calvo A ( 2011 ) Inhibition of 10 ( 96 ): 10 .1186 158. Lin L , Fuchs J , Li C , Olson V , Bekaii-Saab T , Lin J ( 2011 ) STAT3 signaling pathway is necessary for cell survival and tumorsphere forming capacity in ALDH?/CD133? stem cell- 416 ( 3 ): 246 - 251 159. Korkaya H , Paulson A , Iovino F , Wicha MS ( 2008 ) HER2 tumorigenesis and invasion. Oncogene 27 ( 47 ): 6120 - 6130 160. Alam M , Ahmad R , Rajabi H , Kharbanda A , Kufe D ( 2013 ) MUC1-C oncoprotein activates ERK ? C/EBPb signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells . J Biol Chem 288 ( 43 ): 30892 - 30903 161. Rosenthal DT , Zhang J , Bao L , Zhu L , Wu Z , Toy K , Kleer CG , Merajver SD ( 2012 ) RhoC impacts the metastatic potential and abundance of breast cancer stem cells . PLoS One 7 ( 7 ): e40979 162. Raha D , Wilson TR , Peng J , Peterson D , Yue P , Evangelista M , Wilson C , Merchant M , Settleman J ( 2014 ) The cancer stem cell tolerant tumor cell subpopulation . Cancer Res 74 ( 13 ): 3579 - 3590 163. Kim SK , Kim H , D-h Lee, T-s Kim , Kim T , Chung C , Koh GY , Kim H , Lim D-S ( 2013 ) Reversing the intractable nature of resistant cancer cells . PLoS One 8 ( 10 ): e78130 164. Chen D , Cui QC , Yang H , Dou QP ( 2006 ) Disulfiram, a clini- 66 ( 21 ): 10425 - 10433 165. Lo¨vborg H, O¨ berg F , Rickardson L , Gullbo J , Nygren P , Larsson R ( 2006 ) Inhibition of proteasome activity, nuclear factor-KB disulfiram. Int J Cancer 118 ( 6 ): 1577 - 1580 166. Cen D , Gonzalez RI , Buckmeier JA , Kahlon RS , Tohidian NB , Meyskens FL ( 2002 ) Disulfiram induces apoptosis in human mela- noma cells: a redox-related process1 . Mol Cancer Ther 1 ( 3 ): 197 - 204 167. Morrison BW , Doudican NA , Patel KR , Orlow SJ ( 2010 ) in melanoma. Melanoma Res 20 ( 1 ): 11 - 20 168. Yip N , Fombon I , Liu P , Brown S , Kannappan V , Armesilla A , Xu B , Cassidy J , Darling J , Wang W ( 2011 ) Disulfiram modulated ROS- cancer stem cell-like properties . Br J Cancer 104 ( 10 ): 1564 - 1574 169. Zhang H , Chen D , Ringler J , Chen W , Cui QC , Ethier SP , Dou QP , Wu G ( 2010 ) Disulfiram treatment facilitates phospho- inositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res 70 ( 10 ): 3996 - 4004 170. Shian S-G , Kao Y-R , Wu FY -H, Wu C-W ( 2003 ) Inhibition of Mol Pharmacol 64 ( 5 ): 1076 - 1084 171. Marikovsky M , Ziv V , Nevo N , Harris-Cerruti C , Mahler O ( 2003 ) Cu/Zn superoxide dismutase plays important role in immune response . J Immunol 170 ( 6 ): 2993 - 3001 172. Marikovsky M , Nevo N , Vadai E , Harris-Cerruti C ( 2002 ) Cu/ Cancer 97 ( 1 ): 34 - 41 173. Cho H , Lee T , Park J , Park K , Sin D , Park Y , Moon Y , Lee K , Yeo J ( 2007 ) Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40 ( 6 ): 1069 174. Duan X , Xiao J , Yin Q , Zhang Z , Yu H , Mao S , Li Y ( 2014 ) Nanotechnology 25 ( 12 ): 125102 175. Nechushtan H , Hamamreh Y , Nidal S , Gotfried M , Baron A , Shalev YI , Nisman B , Peretz T , Peylan-Ramu N ( 2015 ) A phase ogist 20 ( 4 ): 366 - 367 176. Pors K , Loadman PM , Shnyder SD , Sutherland M , Sheldrake ( 2011 ) Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity . Chem Commun 47 ( 44 ): 12062 - 12064 177. Sheldrake HM , Travica S , Johansson I , Loadman PM , Suther- Shnyder SD ( 2013 ) Re-engineering of the Duocarmycin geting CYP1A1 and CYP2W1 for biological activity . J Med Chem 56 ( 15 ): 6273 - 6277 178. Sutherland M , Gill JH , Loadman PM , Laye JP , Sheldrake HM , Illingworth NA , Alandas MN , Cooper PA , Searcey M , Pors K ( 2013 ) metabolically activated by cytochrome P450 1A1 in human transi- tional cell carcinoma of the bladder . Mol Cancer Ther 12 ( 1 ): 27 - 37 179. Travica S , Pors K , Loadman PM , Shnyder SD , Johansson I , Ingelman-Sundberg M ( 2013 ) Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res 19 ( 11 ): 2952 - 2961 180. Neumeister V , Agarwal S , Bordeaux J , Camp RL , Rimm DL ( 2010 ) In situ identification of putative cancer stem cells by mul- tiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis . Am J Pathol 176 ( 5 ): 2131 - 2138 181. Zhong Y , Shen S , Zhou Y , Mao F , Guan J , Lin Y , Xu Y , Sun Q ( 2014 ) ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44?/CD24- pheno- type. Med Oncol 31 ( 3 ): 1 - 8 182. Opdenaker LM , Arnold KM , Pohlig RT , Padmanabhan JS , Flynn DC , Sims-Mourtada J ( 2014 ) Immunohistochemical breast cancer . Breast Cancer 6 : 205 183. Qiu Y , Pu T , Li L , Cheng F , Lu C , Sun L , Teng X , Ye F , Bu H ( 2014 ) The expression of aldehyde dehydrogenase family in breast cancer . J Breast Cancer 17 ( 1 ): 54 - 60 184. Tan EY , Thike AA , Breast Surgical Team at O, Tan PH ( 2013 ) ALDH1 expression is enriched in breast cancers arising in 109 ( 1 ): 109 - 113 185. Liu S , Liu C , Min X , Ji Y , Wang N , Liu D , Cai J , Li K ( 2013 ) nase in ovarian cancer: a meta-analysis . PLoS One 8 ( 11 ): e81050 186. Rasper M , Scha¨fer A , Piontek G , Teufel J , Brockhoff G , Ringel F , Heindl S , Zimmer C , Schlegel J ( 2010 ) Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity . Neuro-oncology: noq070 187. Zhang W , Yan W , You G , Bao Z , Wang Y , Liu Y , You Y , Jiang T ( 2013 ) Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP- primary glioblastoma . Cancer Lett 328 ( 1 ): 120 - 125 188. Gangavarapu KJ , Azabdaftari G , Morrison CD , Miller A , Foster BA , Huss WJ ( 2013 ) Aldehyde dehydrogenase and ATP binding cassette transporter G2 (ABCG2) functional assays isolate dif- ferent populations of prostate stem cells where ABCG2 function Ther 4 ( 5 ): 132 189. Wu J , Mu Q , Thiviyanathan V , Annapragada A , Vigneswaran N ( 2014 ) Cancer stem cells are enriched in Fanconi anemia head and neck squamous cell carcinomas . Int J Oncol 45 ( 6 ): 2365 - 2372 190. Deng Y , Zhou J , Fang L , Cai Y , Ke J , Xie X , Huang Y , Huang M , Wang J ( 2014 ) ALDH1 is an independent prognostic factor radiochemotherapy. Br J Cancer 110 ( 2 ): 430 - 434 191. Patlolla JM , Qian L , Biddick L , Zhang Y , Desai D , Amin S , Lightfoot S , Rao CV ( 2013 ) b-Escin Inhibits NNK-induced lung adenocarcinoma and ALDH1A1 and RhoA/Rock expression in A/J mice and growth of H460 human lung cancer cells . Cancer Prev Res 6 ( 10 ): 1140 - 1149 192. Giacalone NJ , Den RB , Eisenberg R , Chen H , Olson SJ , Mas- sion PP , Carbone DP , Lu B ( 2013 ) ALDH7A1 expression is non-small-cell lung carcinoma . Future Oncol 9 ( 5 ): 737 - 745 193. Boonyaratanakornkit JB , Yue L , Strachan LR , Scalapino KJ , LeBoit PE , Lu Y , Leong SP , Smith JE , Ghadially R ( 2010 ) Dermatol 130 ( 12 ): 2799 - 2808 194. Z-l Yang, Yang L, Zou Q , Yuan Y , Li J , Liang L , Zeng G , Chen S ( 2013 ) Positive ALDH1A3 and negative GPX3 expressions Markers 35 ( 3 ): 10


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs10585-015-9755-9.pdf

Mauricio Rodriguez-Torres, Alison L. Allan. Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors, Clinical & Experimental Metastasis, 2016, 97-113, DOI: 10.1007/s10585-015-9755-9